Precision BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Precision BioSciences Inc DTIL.OQ reported a quarterly adjusted loss of $2.22​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.06. The mean expectation of four analysts for the quarter was for a loss of $1.96 per share. Wall Street expected results to range from $-2.77 to -42 cents per share.

• Revenue fell 90.9% to $638.00 thousand from a year ago; analysts expected $4.28 million.

• Precision BioSciences Inc's reported EPS for the quarter was a loss of $2.22​.

• The company reported a quarterly loss of $17.75 million.

• Precision BioSciences Inc shares had risen by 33.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Precision BioSciences Inc is $29.50

This summary was machine generated from LSEG data March 26 at 11:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)